Skip to main content

Advertisement

Table 1 Descriptive Characteristics (\( \overline{X} \)±SD)

From: The effects of Shilajit supplementation on fatigue-induced decreases in muscular strength and serum hydroxyproline levels

  Pre-Supplementation Post-Supplementation
Total Upper Lower Total Upper Lower
MVIC (Nm)
 Low Dose 376.1 ± 79.1 447.3 ± 45.8 311.5 ± 30.9 360.6 ± 95.3 431.9 ± 54.2 295.8 ± 76.3
 High Dose 366.0 ± 53.5 409.8 ± 44.2 326.3 ± 18.0 335.3 ± 53.0 351.6 ± 59.7 320.5 ± 43.7
 Placebo 366.3 ± 81.8 431.7 ± 60.5 306.8 ± 43.8 346.8 ± 63.6 370.4 ± 50.8 325.3 ± 68.5
% Decline MVIC
 Low Dose 16.5 ± 9.5 19.8 ± 9.1 14.1 ± 9.5 16.0 ± 12.2 18.2 ± 9.8 14.0 ± 14.1
 High Dose 14.1 ± 9.4 16.6 ± 10.8 11.8 ± 7.6 9.0 ± 6.9 9.0 ± 7.5 9.1 ± 6.6
 Placebo 13.0 ± 10.1 12.4 ± 10.0 14.2 ± 11.1 14.2 ± 6.9 14.8 ± 6.2 13.8 ± 7.8
Peak Torque (Nm)
 Low Dose 224.5 ± 49.0 267.4 ± 24.0 185.6 ± 28.0 253.0 ± 48.8 274.2 ± 28.6 233.7 ± 56.3
 High Dose 231.8 ± 42.5 266.3 ± 20.3 200.5 ± 31.1 240.2 ± 43.4 264.0 ± 31.2 218.7 ± 42.7
 Placebo 236.9 ± 56.3 283.3 ± 36.4 194.8 ± 32.1 246.1 ± 42.9 254.5 ± 43.2 238.5 ± 43.2
% Decline Peak Torque
 Low Dose 44.6 ± 15.0 46.9 ± 16.6 42.5 ± 13.8 51.5 ± 15.5 49.3 ± 15.7 53.4 ± 15.9
 High Dose 42.0 ± 16.8 41.2 ± 19.4 42.7 ± 15.0 46.5 ± 16.5 50.0 ± 13.2 43.4 ± 19.2
 Placebo 38.1 ± 18.9 42.2 ± 19.6 34.4 ± 18.3 41.2 ± 16.4 50.6 ± 15.6 39.7 ± 18.1
HYP (μg·mL− 1)
 Low Dose 2.25 ± 1.1 3.11 ± 0.9 1.48 ± 0.3 1.89 ± 0.8 2.38 ± 0.9 1.45 ± 0.5
 High Dose 2.26 ± 0.8 2.87 ± 0.9 1.70 ± 0.1 1.66 ± 0.7 1.50 ± 0.6 1.81 ± 0.8
 Placebo 2.12 ± 0.9 2.80 ± 0.8 1.50 ± 0.3 2.02 ± 0.9 2.40 ± 0.9 1.68 ± 0.6
% Change HYP
 Low Dose 9.63 ± 27.8 11.5 ± 34.0 7.2 ± 23.3 20.3 ± 70.2 5.5 ± 65.2 32.9 ± 78.9
 High Dose 15.6 ± 32.9 23.6 ± 33.8 4.8 ± 31.3 24.0 ± 62.1 39.8 ± 83.1 11.2 ± 33.2
 Placebo 17.2 ± 47.7 4.3 ± 35.7 41.1 ± 50.7 29.7 ± 92.0 0.81 ± 57.6 60.7 ± 115.7